We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Calcium Levels Linked to Ovarian Cancer

By LabMedica International staff writers
Posted on 13 Feb 2013
Print article
High blood calcium levels might predict ovarian cancer, the most fatal of the gynecological cancers.

Many ovarian cancers express parathyroid hormone-related protein, which acts to raise calcium levels in serum, which may be a biomarker for ovarian cancer.

Cancer epidemiologists at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA) measured total and ionized serum calcium levels using ion-specific electrodes. They were pH-adjusted because the protein binding of calcium is affected by pH; ionized calcium in blood is commonly corrected to standard pH. Serum samples were collected as part of Third National Health and Nutrition Examination Surveys (NHANES III) between 1988 and 1994 from two nationally representative prospective cohorts.

Eleven ovarian cancer deaths were observed over 95,556 person-years of follow-up through December 31, 2006, representing 137,404 ovarian cancer deaths in the United States of America. The range in total serum calcium in cases was 2.14–2.44 mmol/L and for ionized serum calcium was 1.17–1.31 mmol/L. The normal reference range for total serum calcium is approximately 2.17–2.52 mmol/L and 1.12–1.32 mmol/L for ionized serum calcium. In the second cohort, there were eight ovarian cancer cases in over 31,089 person-years of follow-up. The range of total serum calcium was 1.98–2.93 mmol/L. The relative hazard for fatal ovarian cancer was 1.52 per 0.1 mmol/L increase in total serum calcium and 2.44 per 0.1 mmol/L increase in ionized serum calcium.

Gary G. Schwartz, PhD, the lead author of the study, said "One approach to cancer biomarker discovery is to identify a factor that is differentially expressed in individuals with and without cancer and to examine that factor's ability to detect cancer in an independent sample of individuals." His coauthor added, "Everyone's got calcium and the body regulates it very tightly. We know that some rare forms of ovarian cancer are associated with very high calcium, so it's worth considering whether more common ovarian cancers are associated with moderately high calcium."

The authors concluded that this biomarker, the higher levels of calcium in serum, were significantly positively associated with the risk of ovarian cancer in two prospective cohorts. The principal limitation of this study is the small number of cases. Conversely, the study has several strengths: it is prospective, uses population-based data from two nationally representative cohorts, and is the first to study ionized serum calcium. The existence of stored sera from sample sets of women with and without ovarian cancer should facilitate the confirmation or refutation of the association between serum calcium and ovarian cancer. The study was published January 9, 2013, in the journal Gynecologic Oncology.

Related Links:
Wake Forest Baptist Medical Center


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.